Clinical Trials match your criteria
-
WARRIOR
Women’s Ischemia Trial to Reduce Events in Non-Obstructive CAD (WARRIOR)
-
Phase 2 study of Autologous TIL's for patients with solid tumors
A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN-144 or LN-145) in Patients with Solid Tumors
-
Pediatric Hepatic Malignancy International Therapeutic Trial
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
-
Head Start 4: Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors
Clinical and Molecular Risk-Tailored Intensive and Compressed Induction Chemotherapy Followed by Consolidation with Either Single Cycle (Low Risk Patients) or Randomization (High Risk Patients) to Either Single-Cycle or to Three Tandem Cycles of Marrow-Ablative Chemotherapy with Autologous Hematopoietic Progenitor Cell Rescue
-
Web-Based Physical Activity Intervention to Improve Health in Children with Leukemia
A Randomized Web-based Physical Activity Intervention among Children and Adolescents with Acute Lymphoblastic Leukemia
-
Neoadjuvant therapy for abnormal HER2- Signaling
An Open-Label Phase II Trial to Evaluate the Efficacy and Safety of Neoadjuvant Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel Plus Trastuzumab and Pertuzumab in Early Stage HER2-Negative Breast Cancer Patients Selected with a Test Measuring Live Cell HER2 Signaling Transduction (FACT 1)
-
Use of Optune NovoTTF-200A System in Combination with Temozolomide and Bevacizumab with High Grade Glioma and Ependymoma
A Phase I Trial of the Optune NovoTTF-200A System in Pediatric Patients With High-grade Glioma and Ependymoma
-
Pediatric Precision Laboratory Advanced Neuroblastoma Therapy
A Study Using Molecular Guided Therapy With Induction Chemotherapy Followed by a Randomized Controlled Trial of Standard Immunotherapy With or Without DFMO Followed by DFMO Maintenance for Subjects With Newly Diagnosed High-Risk Neuroblastoma
-
AMPLATZER PFO
AMPLATZER PFO Occluder Post Approval Study